Type I interferons and natural killer cell regulation in cancer

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Müller, Lena ^a   Aigner, Petra ^a   Stoiber, Dagmar ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticancer therapy; Innate immunity; Interferon signaling; Natural killer cells; Tumor microenvironment; Tumor surveillance; Type I interferon

Indexed keywords

INTERFERON;

CANCER THERAPY; CELL FUNCTION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL (TOPIC); CROSS PRESENTATION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASM; MEMORY CELL; METASTASIS; NATURAL KILLER CELL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 85017110803     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00304     Document Type: Review

References (125)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 147:258-67. doi:10.1098/rspb.1957.0048
2. Decker T, Müller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol (2005) 5:675-87. doi:10.1038/nri1684
3. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2014) 14:36-49. doi:10.1038/nri3581
4. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev (2004) 202:8-32. doi:10.1111/j.0105-2896.2004.00204.x
5. Hertzog PJ, Williams BRG. Fine tuning type I interferon responses. Cytokine Growth Factor Rev (2013) 24:217-25. doi:10.1016/j.cytogfr.2013.04.002
6. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell (2006) 124:783-801. doi:10.1016/j.cell.2006.02.015
7. Uematsu S, Akira S. Toll-like receptors and type I interferons. J Biol Chem (2007) 282:15319-23. doi:10.1074/jbc.R700009200
8. Cavlar T, Ablasser A, Hornung V. Induction of type I IFNs by intracellular DNA-sensing pathways. Immunol Cell Biol (2012) 90:474-82. doi:10.1038/icb.2012.11
9. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 3:651-62. doi:10.1038/nrm909
10. Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity (2012) 36:503-14. doi:10.1016/j.immuni.2012.03.013
11. Silvennoinen O, Ihle JN, Schlessinger J, Levy DE. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature (1993) 366:583-5. doi:10.1038/366583a0
12. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604
13. Du Z, Wei L, Murti A, Pfeffer SR, Fan M, Yang CH, et al. Non-conventional signal transduction by type 1 interferons: the NF-κB pathway. J Cell Biochem (2007) 102:1087-94. doi:10.1002/jcb.21535
14. Gough DJ, Messina NL, Clarke CJP, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity (2012) 36:166-74. doi:10.1016/j.immuni.2012.01.011
15. Essers MAG, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature (2009) 458:904-8. doi:10.1038/nature07815
16. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med (2009) 15:696-700. doi:10.1038/nm.1973
17. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 416:744-9. doi:10.1038/416744a
18. Tovey MG, Streuli M, Gresser I, Gugenheim J, Blanchard B, Guymarho J, et al. Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc Natl Acad Sci U S A (1987) 84:5038-42. doi:10.1073/pnas.84.14.5038
19. Gresser I. Biologic effects of interferons. J Invest Dermatol (1990) 95:66S-71S. doi:10.1111/1523-1747.ep12874776
20. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 424:516-23. doi:10.1038/nature01850
21. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 15:405-14. doi:10.1038/nri3845
22. Tschurtschenthaler M, Wang J, Fricke C, Fritz TMJ, Niederreiter L, Adolph TE, et al. Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut (2014) 63:1921-31. doi:10.1136/gutjnl-2013-305863
23. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity (2006) 25:373-81. doi:10.1016/j.immuni.2006.08.007
24. Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 6:722-9. doi:10.1038/ni1213
25. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 16:131-44. doi:10.1038/nrc.2016.14
26. Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8a+ dendritic cells. J Exp Med (2011) 208:2005-16. doi:10.1084/jem.20101159
27. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 208:1989-2003. doi:10.1084/jem.20101158
28. Fuertes MB, Woo S-R, Burnett B, Fu Y-X, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol (2013) 34:67-73. doi:10.1016/j.it.2012.10.004
29. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, et al. Type I IFNs control antigen retention and survival of CD8a(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol (2011) 186:5142-50. doi:10.4049/jimmunol.1004163
30. Schiavoni G, Mattei F, Gabriele L. Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response. Front Immunol (2013) 4:483. doi:10.3389/fimmu.2013.00483
31. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol (2001) 167:1179-87. doi:10.4049/jimmunol.167.3.1179
32. Huntington ND. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol Cell Biol (2014) 92:210-3. doi:10.1038/icb.2014.1
33. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol (2010) 22:333-40. doi:10.1016/j.coi.2010.02.013
34. Granot Z, Jablonska J. Distinct functions of neutrophil in cancer and its regulation. Mediators Inflamm (2015) 2015:701067. doi:10.1155/2015/701067
35. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest (2010) 120:1151-64. doi:10.1172/JCI37223
36. Andzinski L, Wu C-F, Lienenklaus S, Kröger A, Weiss S, Jablonska J. Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN-β. Int J Cancer (2015) 136:572-83. doi:10.1002/ijc.28957
37. Jablonska J, Wu C-F, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β. Int J Cancer (2014) 134:1346-58. doi:10.1002/ijc.28551
38. Wu C-F, Andzinski L, Kasnitz N, Kröger A, Klawonn F, Lienenklaus S, et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int J Cancer (2015) 137:837-47. doi:10.1002/ijc.29444
39. Woo S-R, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol (2015) 33:445-74. doi:10.1146/annurev-immunol-032414-112043
40. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 190:3783-97. doi:10.4049/jimmunol.1201449
41. Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res (2011) 17:1765-75. doi:10.1158/1078-0432.CCR-10-2672
42. Pace L, Vitale S, Dettori B, Palombi C, La Sorsa V, Belardelli F, et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol (2010) 184:5969-79. doi:10.4049/jimmunol.0900526
43. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 72:5188-97. doi:10.1158/0008-5472.CAN-11-3468
44. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-a suppresses cAMP to disarm human regulatory T cells. Cancer Res (2013) 73:5647-56. doi:10.1158/0008-5472.CAN-12-3788
45. Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K. Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther (2014) 21:532-41. doi:10.1038/cgt.2014.60
46. Biron CA. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol (1999) 2:374-81. doi:10.1016/S1369-5274(99)80066-6
47. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol (2000) 165:3571-7. doi:10.4049/jimmunol.165.7.3571
48. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei X, Liew FY, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol (2002) 169:4279-87. doi:10.4049/jimmunol.169.8.4279
49. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol (2000) 165:2665-70. doi:10.4049/jimmunol.165.5.2665
50. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol (2001) 13:459-63. doi:10.1093/intimm/13.4.459
51. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med (2004) 200:1325-35. doi:10.1084/jem.20041522
52. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 172:2048-58. doi:10.4049/jimmunol.172.4.2048
53. Swann JB, Hayakawa Y, Zerafa N, Sheehan KCF, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 178:7540-9. doi:10.4049/jimmunol.178.12.7540
54. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol (2011) 11:645-57. doi:10.1038/nri3044
55. Huntington ND, Vosshenrich CAJ, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol (2007) 7:703-14. doi:10.1038/nri2154
56. Carotta S, Pang SHM, Nutt SL, Belz GT. Identification of the earliest NK-cell precursor in the mouse BM. Blood (2011) 117:5449-52. doi:10.1182/blood-2010-11-318956
57. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol (2013) 34:573-82. doi:10.1016/j.it.2013.07.005
58. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol (2013) 13:145-9. doi:10.1038/nri3365
59. Huntington ND, Nutt SL, Carotta S. Regulation of murine natural killer cell commitment. Front Immunol (2013) 4:14. doi:10.3389/fimmu.2013.00014
60. Geiger TL, Sun JC. Development and maturation of natural killer cells. Curr Opin Immunol (2016) 39:82-9. doi:10.1016/j.coi.2016.01.007
61. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood (2009) 113:5488-96. doi:10.1182/blood-2008-10-187179
62. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 176:1517-24. doi:10.4049/jimmunol.176.3.1517
63. Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, Degli-Esposti MA, et al. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 178:4764-70. doi:10.4049/jimmunol.178.8.4764
64. Takeda K, Cretney E, Hayakawa Y, Ota T, Akiba H, Ogasawara K, et al. TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2005) 105:2082-9. doi:10.1182/blood-2004-08-3262
65. Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, et al. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology (2012) 1:1027-37. doi:10.4161/onci.21284
66. Guan J, Miah SMS, Wilson ZS, Erick TK, Banh C, Brossay L. Role of type I interferon receptor signaling on NK cell development and functions. PLoS One (2014) 9:e111302. doi:10.1371/journal.pone.0111302
67. O'Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Immunity (2015) 43:634-45. doi:10.1016/j.immuni.2015.09.013
68. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol (2016) 16:112-23. doi:10.1038/nri.2015.9
69. Majewska-Szczepanik M, Paust S, von Andrian UH, Askenase PW, Szczepanik M. Natural killer cell-mediated contact sensitivity develops rapidly and depends on interferon-a, interferon-γ and interleukin-12. Immunology (2013) 140:98-110. doi:10.1111/imm.12120
70. Biron CA, Tarrio ML. Immunoregulatory cytokine networks: 60 years of learning from murine cytomegalovirus. Med Microbiol Immunol (2015) 204:345-54. doi:10.1007/s00430-015-0412-3
71. Beverley PCL, Ruzsics Z, Hey A, Hutchings C, Boos S, Bolinger B, et al. A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis. J Immunol (2014) 193:2306-16. doi:10.4049/jimmunol.1302523
72. Beaulieu AM, Zawislak CL, Nakayama T, Sun JC. The transcription factor Zbtb32 controls the proliferative burst of virus-specific natural killer cells responding to infection. Nat Immunol (2014) 15:546-53. doi:10.1038/ni.2876
73. Madera S, Rapp M, Firth MA, Beilke JN, Lanier LL, Sun JC. Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. J Exp Med (2016) 213:225-33. doi:10.1084/jem.20150712
74. Lawler C, Tan CSE, Simas JP, Stevenson PG. Type I interferons and NK cells restrict gammaherpesvirus lymph node infection. J Virol (2016) 90:9046-57. doi:10.1128/JVI.01108-16
75. Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest (2004) 114:1650-8. doi:10.1172/JCI22315
76. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell (2006) 10:77-87. doi:10.1016/j.ccr.2006.05.025
77. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood (2011) 117:1565-73. doi:10.1182/blood-2010-06-291633
78. Marçais A, Viel S, Grau M, Henry T, Marvel J, Walzer T. Regulation of mouse NK cell development and function by cytokines. Front Immunol (2013) 4:450. doi:10.3389/fimmu.2013.00450
79. Croce M, Rigo V, Ferrini S. IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res (2015) 2015:1-15. doi:10.1155/2015/696578
80. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 26:503-17. doi:10.1016/j.immuni.2007.03.006
81. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity (2007) 26:798-811. doi:10.1016/j.immuni.2007.04.010
82. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 5:112-24. doi:10.1038/nri1549
83. Verbist KC, Klonowski KD. Functions of IL-15 in anti-viral immunity: multiplicity and variety. Cytokine (2012) 59:467-78. doi:10.1016/j.cyto.2012.05.020
84. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity (1998) 9:669-76. doi:10.1016/S1074-7613(00)80664-0
85. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 5:405-11. doi:10.1038/7403
86. van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol (2003) 171:5842-52. doi:10.4049/jimmunol.171.11.5842
87. Chiba S, Ikushima H, Ueki H, Yanai H, Kimura Y, Hangai S, et al. Recognition of tumor cells by dectin-1 orchestrates innate immune cells for anti-tumor responses. Elife (2014) 3:e04177. doi:10.7554/eLife.04177
88. Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, et al. Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med (2010) 207:2675-87. doi:10.1084/jem.20091573
89. Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity (2014) 40:961-73. doi:10.1016/j.immuni.2014.05.003
90. Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, Sharma P, et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity (2014) 40:949-60. doi:10.1016/j.immuni.2014.05.004
91. Moro H, Otero DC, Tanabe Y, David M. T cell-intrinsic and-extrinsic contributions of the IFNAR/STAT1-axis to thymocyte survival. PLoS One (2011) 6:e24972. doi:10.1371/journal.pone.0024972
92. Zietara N, Lyszkiewicz M, Gekara N, Puchalka J, Dos Santos VAPM, Hunt CR, et al. Absence of IFN-beta impairs antigen presentation capacity of splenic dendritic cells via down-regulation of heat shock protein 70. J Immunol (2009) 183:1099-109. doi:10.4049/jimmunol.0803214
93. Lee CK, Gimeno R, Levy DE. Differential regulation of constitutive major histocompatibility complex class I expression in T and B lymphocytes. J Exp Med (1999) 190:1451-64. doi:10.1084/jem.190.10.1451
94. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 188:2375-80. doi:10.1084/jem.188.12.2375
95. Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol (1999) 163:1906-13
96. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 7:94-100. doi:10.1038/83416
97. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 168:1356-61. doi:10.4049/jimmunol.168.3.1356
98. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol (2001) 31:3138-46. doi:10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B
99. Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, et al. DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Rep (2015) 11:785-97. doi:10.1016/j.celrep.2015.03.069
100. Katlinskaya YV, Carbone CJ, Yu Q, Fuchs SY. Type 1 interferons contribute to the clearance of senescent cell. Cancer Biol Ther (2015) 16:1214-9. doi:10.1080/15384047.2015.1056419
101. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol (2006) 176:905-13. doi:10.4049/jimmunol.176.2.905
102. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung H-P, Weller M, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 155:172-82. doi:10.1016/j.jneuroim.2004.06.013
103. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 9:133-45. doi:10.1038/sj/mn/7800123
104. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of IRF7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 18:1224-31. doi:10.1038/nm.2830
105. Eyles J, Puaux A-L, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 120:2030-9. doi:10.1172/JCI42002
106. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 507:508-12. doi:10.1038/nature12998
107. Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, et al. Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol Res (2015) 3:1207-17. doi:10.1158/2326-6066.CIR-15-0065
108. Kitamura T, Qian B-Z, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol (2015) 15:73-86. doi:10.1038/nri3789
109. Sceneay J, Chow MT, Chen A, Halse HM, Wong CSF, Andrews DM, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res (2012) 72:3906-11. doi:10.1158/0008-5472.CAN-11-3873
110. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2016) 16:7-19. doi:10.1038/nrc.2015.5
111. Ferrantini M, Capone I, Belardelli F. Interferon-a and cancer: mechanisms of action and new perspectives of clinical use. Biochimie (2007) 89:884-93. doi:10.1016/j.biochi.2007.04.006
112. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity (2010) 43:204-9. doi:10.3109/08916930903510880
113. Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-a. Eur J Haematol (2015) 94:227-34. doi:10.1111/ejh.12420
114. Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-a in the treatment of chronic myeloid leukemia. Leukemia (2013) 27:803-12. doi:10.1038/leu.2012.313
115. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 39:74-88. doi:10.1016/j.immuni.2013.06.014
116. Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood (2005) 105:2428-35. doi:10.1182/blood-2004-09-3458
117. Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother (2015) 64:225-35. doi:10.1007/s00262-014-1629-5
118. Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. IFN-a directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 186:2772-9. doi:10.4049/jimmunol.1003208
119. Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 116:2286-94. doi:10.1182/blood-2010-02-271874
120. Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, et al. Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFN? that induce PD-L1 expression in head and neck cancer. Cancer Res (2016) 76:1031-43. doi:10.1158/0008-5472.CAN-15-2001
121. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med (2016) 375:819-29. doi:10.1056/NEJMoa1604958
122. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 6:226ra32. doi:10.1126/scitranslmed.3008095
123. Jiang W, Zhang C, Tian Z, Zhang J. hIFN-a gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther (2013) 20:1062-9. doi:10.1038/gt.2013.31
124. Nagler A, Ackerstein A, Or R, Naparstek E, Slavin S. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood (1997) 89:3951-9
125. Shevtsov M, Multhoff G. Immunological and translational aspects of NK cell-based antitumor immunotherapies. Front Immunol (2016) 7:492. doi:10.3389/fimmu.2016.00492